Has the risk of liver re‐transplantation improved over the two decades?

医学 肝移植 危险系数 肝病 队列 置信区间 内科学 比例危险模型 移植 外科
作者
Miho Akabane,Yuki Bekki,Yuki Imaoka,Yosuke Inaba,Carlos O. Esquivel,Allison J. Kwong,Marc L. Melcher,Kazunari Sasaki
出处
期刊:Clinical transplantation [Wiley]
卷期号:37 (12)
标识
DOI:10.1111/ctr.15127
摘要

Abstract Background Despite advancements in liver transplantation (LT) over the past two decades, liver re‐transplantation (re‐LT) presents challenges. This study aimed to assess improvements in re‐LT outcomes and contributing factors. Methods Data from the United Network for Organ Sharing database (2002–2021) were analyzed, with recipients categorized into four‐year intervals. Trends in re‐LT characteristics and postoperative outcomes were evaluated. Results Of 128,462 LT patients, 7254 received re‐LT. Graft survival (GS) for re‐LT improved (91.3%, 82.1%, and 70.8% at 30 days, 1 year, and 3 years post‐LT from 2018 to 2021). However, hazard ratios (HRs) for GS remained elevated compared to marginal donors including donors after circulatory death (DCD), although the difference in HRs decreased in long‐term GS. Changes in re‐LT causes included a reduction in hepatitis C recurrence and an increase in graft failure post‐primary LT involving DCD. Trends identified included recent decreased cold ischemic time (CIT) and increased distance from donor hospital in re‐LT group. Meanwhile, DCD cohort exhibited less significant increase in distance and more marked decrease in CIT. The shortest CIT was recorded in urgent re‐LT group. The highest Model for End‐Stage Liver Disease score was observed in urgent re‐LT group, while the lowest was recorded in DCD group. Analysis revealed shorter time interval between previous LT and re‐listing, leading to worse outcomes, and varying primary graft failure causes influencing overall survival post‐re‐LT. Discussion While short‐term re‐LT outcomes improved, challenges persist compared to DCD. Further enhancements are required, with ongoing research focusing on optimizing risk stratification models and allocation systems for better LT outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
彭于晏应助科研通管家采纳,获得10
1秒前
Jasper应助科研通管家采纳,获得10
1秒前
无花果应助科研通管家采纳,获得10
1秒前
李健应助科研通管家采纳,获得10
1秒前
Yxblin完成签到,获得积分10
1秒前
Lucas应助科研通管家采纳,获得10
1秒前
所所应助科研通管家采纳,获得10
1秒前
1秒前
rainbow应助科研通管家采纳,获得10
1秒前
搜集达人应助科研通管家采纳,获得10
1秒前
LewisAcid应助LKX采纳,获得20
1秒前
Twonej应助科研通管家采纳,获得50
1秒前
nuaa_shy应助科研通管家采纳,获得10
1秒前
天天快乐应助科研通管家采纳,获得10
1秒前
天天快乐应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
orixero应助科研通管家采纳,获得10
2秒前
zz应助科研通管家采纳,获得10
2秒前
星辰大海应助科研通管家采纳,获得10
2秒前
baiseqiutian完成签到,获得积分10
2秒前
zz应助科研通管家采纳,获得10
2秒前
2秒前
英姑应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
2秒前
2秒前
NexusExplorer应助科研通管家采纳,获得10
2秒前
2秒前
李健应助科研通管家采纳,获得10
2秒前
Tian发布了新的文献求助10
2秒前
2秒前
Ava应助科研通管家采纳,获得10
2秒前
2秒前
一叶知秋完成签到,获得积分10
2秒前
2秒前
rainbow应助科研通管家采纳,获得10
3秒前
慕青应助科研通管家采纳,获得10
3秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Aerospace Standards Index - 2026 ASIN2026 3000
Relation between chemical structure and local anesthetic action: tertiary alkylamine derivatives of diphenylhydantoin 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Work Engagement and Employee Well-being 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6069496
求助须知:如何正确求助?哪些是违规求助? 7901300
关于积分的说明 16333491
捐赠科研通 5210575
什么是DOI,文献DOI怎么找? 2786933
邀请新用户注册赠送积分活动 1769757
关于科研通互助平台的介绍 1648011